Caruso I, Pietrogrande V
Department of Rheumatology, L. Sacco Hospital, Milan, Italy.
Am J Med. 1987 Nov 20;83(5A):66-71. doi: 10.1016/0002-9343(87)90854-0.
In a double-blind study, the efficacy and tolerability of S-adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and naproxen in the treatment of osteoarthritis of the hip, knee, spine, and hand. Thirty-three centers, 18 rheumatologic and 15 orthopedic, participated in this study. A total of 734 subjects, including 582 with coxarthrosis (hip osteoarthritis) or gonarthrosis (knee osteoarthritis), were enrolled. SAMe administered orally at a dose of 1,200 mg daily was shown to exert the same analgesic activity as naproxen at a dose of 750 mg daily. Both drugs were more effective than placebo (p less than 0.01). Tolerability of SAMe was significantly better than that of naproxen, both in terms of physicians' (p less than 0.025) and patients' (p less than 0.01) judgments and in terms of the number of patients with side effects (p less than 0.05). There was no difference between SAMe and placebo in the number of side effects. Ten patients in the SAMe group and 13 in the placebo group withdrew from the study because of intolerance to the drug.
在一项双盲研究中，对S-腺苷甲硫氨酸（SAMe）与安慰剂和萘普生治疗髋、膝、脊柱和手部骨关节炎的疗效和耐受性进行了评估。33个中心（18个风湿病科和15个骨科）参与了这项研究。总共招募了734名受试者，其中包括582名患有髋骨关节炎或膝骨关节炎的患者。结果显示，每日口服1200毫克剂量的SAMe与每日口服750毫克剂量的萘普生具有相同的镇痛活性。两种药物均比安慰剂更有效（p<0.01）。无论是从医生（p<0.025）和患者（p<0.01）的判断来看，还是从出现副作用的患者数量来看（p<0.05），SAMe的耐受性都明显优于萘普生。SAMe组和安慰剂组在副作用数量上没有差异。SAMe组有10名患者和安慰剂组有13名患者因对药物不耐受而退出研究。
